Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000861752
Ethics application status
Approved
Date submitted
25/07/2013
Date registered
5/08/2013
Date last updated
1/08/2019
Date data sharing statement initially provided
1/08/2019
Date results information initially provided
1/08/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Predicting and preventing leukaemia in children with Down syndrome.
Query!
Scientific title
A study of GATA-1 gene mutations to predict leukaemia in children with Down syndrome.
Query!
Secondary ID [1]
282794
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
The PreP 21 Study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Transient Myeloid Disorder (TMD)
289566
0
Query!
Myeloid Leukaemia of Down Syndrome (ML-DS) which includes Acute Megakaryoblastic Leukaemia (AMKL) and myelodysplasia
289567
0
Query!
Condition category
Condition code
Blood
289909
289909
0
0
Query!
Haematological diseases
Query!
Cancer
289910
289910
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
4
Query!
Target follow-up type
Years
Query!
Description of intervention(s) / exposure
The aim of the study is to better understand the relationship between GATA-1 gene mutations and development of transient myeloproliferative disorder (TMD) and myeloid leukaemia in children with Down syndrome (ML-DS), particularly acute megakaryoblastic leukaemia (AMKL). GATA-1 gene mutation analysis will be performed on genetic material extracted from blood.
A small sample of blood (about a teaspoon full) will be collected for GATA-1 gene mutation analysis. Another small sample of blood will be collected for a full blood count (FBC) for haematological assessment.
Methods and testing
Patients enroled on this protocol will be followed up by their primary clinician and study team to ensure that required blood collections are performed. The study will follow-up participants from birth or time of consent until the age of 4 years (48 months).
Blood collection timepoints are designed to coincide as much as possible with routine testing procedures required for children with Down syndrome.
Study samples and a full blood count (FBC) sample will be collected at the time of consent. Ideally this would be within the first few weeks after birth. All children with Down syndrome are eligible to participate in the study, regardless of any health issues they may have.
Participants who do not develop TMD will have blood collected at 3,6,12,18,24,36 and 48 months.
Participants who develop TMD will have additional blood collections to those stated above at 9, 30 and 42 months. These extra blood collections are required for monitoring the TMD.
Participants who develop AMKL will have blood collected for the study at diagnosis. After this they will no longer be required to have blood collected for study purposes.
Haematological evaluation of FBC will help clinicians monitor levels of red and white blood cells in participants.
Study samples for GATA-1 gene mutation analysis will be sent to a specialised lab for testing. Results of these tests will establish methods for GATA-1 gene mutation testing in future children with Down syndrome.
Primary Objectives
-to assess levels of GATA-1 gene mutations detected in children with Down syndrome found to have TMD/ML-DS.
-to identify factors that promote regression of TMD or subsequent progression to ML-DS in children with Down syndrome.
-to evaluate the true incidence of subclinical TMD and explore its relationship to the subsequent formation of AMKL.
Secondary Objectives
-to develop novel techniques that will assess GATA-1 gene mutations in non-TMD or non-AMKL populations in the future.
-to determine how the GATA-1 loss of function mutation contributes to the pre-leukaemic state.
-to assess feasibility of monitoring children with documented TMD or AMKL for minimal residual disease using GATA-1 mutation testing.
-to determine whether children with Down syndrome progressing to ML-DS can be indentified before frank leukaemia develops.
Query!
Intervention code [1]
287489
0
Not applicable
Query!
Comparator / control treatment
Not applicable - Obsevational study
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
289977
0
The prevalence of subclinical TMD/TMD and/or AMKL in children with Down syndrome.
This will be achieved by GATA-1 gene mutation analysis of blood collected for study purposes.
Query!
Assessment method [1]
289977
0
Query!
Timepoint [1]
289977
0
Between birth/consent and 4 years of age
Participants who do not develop TMD will have blood collected at 3,6,12,18,24,36 and 48 months.
Participants who develop TMD will have additional blood collections to those stated above at 9, 30 and 42 months. These extra blood collections are required for monitoring the TMD.
Query!
Primary outcome [2]
290158
0
Detection of subclinical TMD using blood collected for FBC analysis.
FBC analysis will be performed at local pathology laboratories.
Query!
Assessment method [2]
290158
0
Query!
Timepoint [2]
290158
0
Between birth/consent and 4 years of age
Participants who do not develop TMD will have blood collected at 3,6,12,18,24,36 and 48 months.
Participants who develop TMD will have additional blood collections to those stated above at 9, 30 and 42 months. These extra blood collections are required for monitoring the TMD.
Query!
Secondary outcome [1]
304033
0
Development of a novel GATA-1 gene mutation analysis technique as a reliable biomarker for risk of progression to TMD and/or AMKL.
Query!
Assessment method [1]
304033
0
Query!
Timepoint [1]
304033
0
Within the next 5 years.
Query!
Eligibility
Key inclusion criteria
This study is open to children born with Down syndrome or mosaic Down syndrome. The trial is currently open in NSW and may be extended to other states in the future.
Children up to and including the age of 2 years are eligible to enrol in the study.
Children with typical physical characteristics of Down syndrome are eligible for consent before cytogenetic confirmation of diagnosis is made.
Query!
Minimum age
0
Days
Query!
Query!
Maximum age
2
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Participants with incomplete/unsigned consent forms are excluded from the study.
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Date of first participant enrolment
Anticipated
13/08/2013
Query!
Actual
13/08/2013
Query!
Date of last participant enrolment
Anticipated
31/12/2017
Query!
Actual
31/12/2017
Query!
Date of last data collection
Anticipated
31/12/2021
Query!
Actual
Query!
Sample size
Target
500
Query!
Accrual to date
Query!
Final
89
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
1239
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [2]
1240
0
Royal Hospital for Women - Randwick
Query!
Recruitment hospital [3]
1241
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [4]
1242
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [5]
1243
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [6]
1244
0
St George Hospital - Kogarah
Query!
Recruitment hospital [7]
1245
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [8]
1246
0
Fairfield Hospital - Prairiewood
Query!
Recruitment hospital [9]
1247
0
Auburn Hospital & Community Health Services - Auburn
Query!
Recruitment hospital [10]
1248
0
Blacktown Hospital - Blacktown
Query!
Recruitment hospital [11]
1249
0
Nepean Hospital - Kingswood
Query!
Recruitment hospital [12]
1250
0
Canterbury Hospital - Campsie
Query!
Recruitment hospital [13]
1251
0
Bankstown-Lidcombe Hospital - Bankstown
Query!
Recruitment hospital [14]
1252
0
Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [15]
1260
0
Maitland Hospital - Maitland
Query!
Recruitment hospital [16]
1261
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [17]
1262
0
Wollongong Hospital - Wollongong
Query!
Recruitment hospital [18]
1333
0
Lismore Base Hospital - Lismore
Query!
Recruitment hospital [19]
1406
0
John Hunter Children's Hospital - New Lambton
Query!
Recruitment hospital [20]
9614
0
Bathurst Base Hospital - Bathurst
Query!
Recruitment hospital [21]
9615
0
Westmead Hospital - Westmead
Query!
Recruitment postcode(s) [1]
7190
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
7191
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
7192
0
2050 - Camperdown
Query!
Recruitment postcode(s) [4]
7193
0
2217 - Kogarah
Query!
Recruitment postcode(s) [5]
7194
0
2170 - Liverpool
Query!
Recruitment postcode(s) [6]
7195
0
2176 - Prairiewood
Query!
Recruitment postcode(s) [7]
7196
0
2144 - Auburn
Query!
Recruitment postcode(s) [8]
7197
0
2148 - Blacktown
Query!
Recruitment postcode(s) [9]
7198
0
2194 - Campsie
Query!
Recruitment postcode(s) [10]
7199
0
2200 - Bankstown
Query!
Recruitment postcode(s) [11]
7200
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [12]
7202
0
2320 - Maitland
Query!
Recruitment postcode(s) [13]
7203
0
2250 - Gosford
Query!
Recruitment postcode(s) [14]
7204
0
2500 - Wollongong
Query!
Recruitment postcode(s) [15]
7205
0
2480 - Lismore
Query!
Recruitment postcode(s) [16]
7206
0
2751 - Penrith
Query!
Recruitment postcode(s) [17]
7253
0
2305 - New Lambton
Query!
Recruitment postcode(s) [18]
18371
0
2795 - Bathurst
Query!
Funding & Sponsors
Funding source category [1]
287590
0
Charities/Societies/Foundations
Query!
Name [1]
287590
0
Steven Walter Children's Cancer Foundation
Query!
Address [1]
287590
0
PO Box 4610
Sylvania Waters NSW 2224
Query!
Country [1]
287590
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Kids Cancer Centre
Query!
Address
Kids Cancer Centre
Level 1 South
Sydney Children's Hospital
High Street
Randwick NSW 2031
Query!
Country
Australia
Query!
Secondary sponsor category [1]
286418
0
None
Query!
Name [1]
286418
0
Query!
Address [1]
286418
0
Query!
Country [1]
286418
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289558
0
Hunter New England Research Ethics and Governance Unit
Query!
Ethics committee address [1]
289558
0
Hunter New England Local Health District
Locked Bag No 1
New Lambton NSW 2305
Query!
Ethics committee country [1]
289558
0
Australia
Query!
Date submitted for ethics approval [1]
289558
0
27/03/2013
Query!
Approval date [1]
289558
0
11/06/2013
Query!
Ethics approval number [1]
289558
0
HNEHREC 13/04/17/4.07
Query!
Summary
Brief summary
The study is investigating whether patients with Down syndrome and Transient Myeloid Disorder (TMD) who are at a higher risk of developing Myeloid Leukaemia of Down syndrome (ML-DS), including Acute MegaKaryoblastic Leukaemia (AMKL) can be identified through prospective GATA-1 gene mutation testing.
Who is it for?
This study is open to children born with Down syndrome or mosaic Down syndrome who are up to 2 years of age. The trial is currently open in NSW and may be extended to other states in the future.
Children with typical physical characteristics of Down syndrome are eligible for consent before cytogenetic confirmation of diagnosis is made.
Trial details
Participants in this trial will be observed from birth/consent up to until 4 years of age in order to assess the levels of GATA-1 gene mutations and their association with subsequent progression to TMD and/or AMKL.
Blood collection requirements
Observation for signs of potential progression to TMD and/or AMKL will be performed by analysis of periodic full blood counts (FBC). The FBC will be assessed at local laboratories.
Blood collected for study purposes will be stored at a tumour bank. The sample will be studied for GATA-1 gene mutations. It is hoped that results from the study of GATA-1 gene mutations will be used to develop a test that will in the future help predict which children with Down syndrome are more at risk of developing AMKL (acute megakaryoblastic leukaemia).
Participants who do not develop TMD will have blood collected at 3,6,12,18,24,36 and 48 months.
Participants who develop TMD will have additional blood collections to those stated above at 9, 30 and 42 months. These extra blood collections are required for monitoring the TMD.
Participants who develop AMKL will have a final blood collection for study purposes at time of AMKL diagnosis. Blood collection for study purposes will cease at this point.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
41278
0
Prof Glenn Marshall
Query!
Address
41278
0
Kids Cancer Centre
Level 1 South
Sydney Children's Hospital
High Street
Randwick NSW 2031
Query!
Country
41278
0
Australia
Query!
Phone
41278
0
+61 2 9382 1721
Query!
Fax
41278
0
+61 2 9382 1789
Query!
Email
41278
0
[email protected]
Query!
Contact person for public queries
Name
41279
0
Ms Sally Byatt
Query!
Address
41279
0
Kids Cancer Centre
Level 1 South
Sydney Children's Hospital
High Street
Randwick NSW 2031
Query!
Country
41279
0
Australia
Query!
Phone
41279
0
+61 410 346 294
Query!
Fax
41279
0
+61 2 9382 1789
Query!
Email
41279
0
[email protected]
Query!
Contact person for scientific queries
Name
41280
0
Prof Glenn Marshall
Query!
Address
41280
0
Kids Cancer Centre
Level 1 South
Sydney Children's Hospital
High Street
Randwick NSW 2031
Query!
Country
41280
0
Australia
Query!
Phone
41280
0
+61 2 9382 1721
Query!
Fax
41280
0
Query!
Email
41280
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
There will be no IPD sharing.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF